Chronic, recurrent Lymphocytic Leukemia Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

Also known as: Recurrent Chronic Lymphocytic Leukemia

IndicationStatusPhase
DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02332980Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasTreatment